| Literature DB >> 35241718 |
Yi-Teng Hung1,2,3, Shih-Min Lin3,4, I-Shiang Tzeng5, Chau Yee Ng6,7,8.
Abstract
Various treatments are available for auricular keloids, but none has an absolute advantage. A practical and safe therapy to optimize the surgical outcome for auricular keloids is needed. We adopted a multimodal treatment of surgical enucleation, core fillet flap reconstruction, intraoperative corticosteroid injection, and immediate postoperative radiotherapy. There were no routine intralesional corticosteroid injections during follow-up. Keloid recurrences, complications, and risk factors for recurrences were analyzed. The outcome was compared with other published literatures. 45 auricular keloids were included in this study. 85.7% were female with an average age of 27.1 ± 7.5 years, and averaged size was 1.8 × 1.2 ± 0.9 × 0.6 cm. 71.1% were located at ear helix with 28.9% at the ear lobe. Nine keloids were classified as Chang-Park classification type I, 30 for type II, two for type III, and four for IV. The average radiation dosage was 1578.6 cGy. The recurrence rate was 6.7% at an average 24.1-month follow-up. There were no complications of surgery, radiotherapy, and intralesional corticosteroid injection. Our recurrence rate was lower than those in mono-adjuvant therapies of intraoperative corticosteroid injection or radiotherapy. This one-session multimodal approach optimizes treating auricular keloids with a low recurrence rate and minimal post-radiation and long-term corticosteroid injection-related complications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35241718 PMCID: PMC8894473 DOI: 10.1038/s41598-022-07255-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of patients and auricular keloids.
| Mean (N) | SD (%) | |
|---|---|---|
| Age (years) | 27.1 | 7.5 |
| M | 5 | 14.3 |
| F | 30 | 85.7 |
| Surgery | 8 | 17.8 |
| Intralesional injection | 38 | 84.4 |
| Cryotherapy | 4 | 8.9 |
| None | 7 | 15.6 |
| Length × width | 1.8 × 1.2 | 0.9 × 0.6 |
| Ear helix | 32 | 71.1 |
| Ear lobe | 13 | 28.9 |
| I | 9 | 20 |
| II | 30 | 66.7 |
| III | 2 | 4.4 |
| IV | 4 | 8.9 |
F female, M male, N number, SD standard deviation.
Figure 1Clinical photographs of auricular keloids before and after treatment. (a) Two Chang-Park classification type I keloids located on the left ear helix and lobe. (b) Solitary large-sized Chang-Park classification type I keloid on the right ear helix. (c) The patient’s appearance in (a) after 20 months of treatment. (d) The patient’s appearance in (b) after 14 months of treatment.
Treatment outcomes of auricular keloids.
| Mean (N) | SD (%) | |
|---|---|---|
| Dosage (cGY) | 1578.6 | 133.5 |
| Interval (ears) | ||
| 0,1,2 (day after OP) | 20 | 44.4 |
| 0,1,4 (day after OP) | 25 | 55.6 |
| Wound healing (weeks) | 2.4 | 0.7 |
| Recurrence (ears) | 3 | 6.7 |
| Follow-up period (months) | 24.1 | 12.6 |
N number, OP operation, SD standard deviation.
Risk factors of keloid recurrences.
| No recurrence (N = 42) | Recurrence (N = 3) | ||||
|---|---|---|---|---|---|
| Mean (N) | SD (%) | Mean (N) | SD (%) | ||
| Age (years) | 26.8 | 7.3 | 30.3 | 6.1 | 0.438 |
| M | 5 | 11.9 | 0 | 0 | 0.447 |
| F | 37 | 88.1 | 3 | 100 | |
| Surgery | 8 | 19.0 | 0 | 0 | 0.999 |
| Intralesional injection | 35 | 83.3 | 3 | 100 | |
| Cryotherapy | 2 | 4.8 | 2 | 66.7 | |
| None | 7 | 16.7 | 0 | 0 | |
| Length × width | 1.9 × 1.2 | 0.9 × 0.6 | 1.5 × 0.8 | 0.9 × 0.3 | 0.472 |
| Ear helix | 30 | 71.4 | 2 | 66.7 | 0.999 |
| Ear lobe | 12 | 28.6 | 1 | 33.3 | |
| I | 9 | 21.4 | 0 | 0 | 0.900 |
| II | 27 | 64.3 | 3 | 100 | |
| III | 2 | 4.8 | 0 | 0 | |
| IV | 4 | 9.5 | 0 | 0 | |
| Dosage (cGY) | 1584.6 | 136.8 | 1500 | 0 | 0.001 |
| Interval (ears) | |||||
| 0,1,2 (day after OP) | 19 | 45.2 | 1 | 33.3 | 0.999 |
| 0,1,4 (day after OP) | 23 | 54.8 | 2 | 66.7 | |
F female, M male, N number, OP operation, SD standard deviation.
Comparison with previous literatures adopting surgical excision with intraoperative [Triamcinolone acetonide (40 mg/cc)] and postoperative intralesional corticosteroid injection.
| Patient (N) | Keloid (N) | Ethnicity | Age (years) | Sex | Sizea (cm) | Location | Prior OP | Prior IL | Surgery | Scheduled post-OP IL | Recurrence rate (keloid N) | Follow-up | Complication (keloid N) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1[ | 64 | 92 | African American (83%) Caucasian (9%) Hispanic (8%) | 28.3 | F (78%) M (22%) | 1.94 | NA | 25% (23/92) | NA | Total excision ± flap | Post-OP 1st and 2nd month | 23.3% (10/43) | 10.4 years in 43 keloids | 5.4% (5/92); depigmentation (1), scar widening (1), and wound dehiscence (1) |
| 2[ | 12 | 12 | Black (67%) Caucasian (8%) Hispanic (25%) | 29.4 | F (33%) M (67%) | 2.00 | Lobe (100%) | 50% (6/12) | 25% (3/12) | Total excision | Post-OP 1st, 3rd, and 5th week | 33.3% (4/12) | 19 months | No |
| 3[ | 15 | 21 | NA | 24.8 | F (100%) | NA | Lobe (71.4%) Helix (28.6%) | 13.3% (2/15) | 20% (3/15) | Enucleation + core fillet flap | Post-OP 2nd week and monthly dependent on lesion | 9.5% (2/21) | 21.9 months | Flap necrosis and infection, abscess after IL, and neuroma after 2nd OP |
| Our | 35 | 45 | Chinese (97.1%) Caucasian (2.9%) | 27.1 | F (85.7%) M (14.3%) | 1.85 | Lobe (71.1%) Helix (28.9%) | 17.8% (8/45) | 84.4% (38/45) | Enucleation + core fillet flap | No | 6.7% (3/45) | 24.1 months | 2.2% (1/45); seroma (1) |
aSize was shown with averaged longitudinal length.
F female, IL intralesional corticosteroid injection, M male, N number, NA not available, OP operation.
Comparison with previous literatures adopting surgical excision with postoperative radiation therapy.
| Patient (N) | Keloid (N) | Ethnicity | Age (years) | Sex | Location | Prior OP | Surgery | External beam RT | RT regimen (total dose/fraction × dose per fraction) (Gy) | Recurrence rate (keloid N) | Follow-up (months) | Complication (keloid N) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1[ | 23 | 30 | NA | 28 | F (75%) M (35%) | Lobe (100%) | 33.3% (10/30) | Total excision | 6-MeV electron | 15/3 × 5; 1 Fr. in post-OP 2 h and 2 Fr. in post-OP 2–3 days | 13.3% (4/30) | 26 | Hyperpigmentation 13.3% (4/30) |
| 2[ | 57 | 63 | NA | NA | F (91.2%) M (8.8%) | NA | 0% | Total excision: 59% (37/63) Enucleation: 41% (26/63) | 4-MeV electron | 15/3 × 5; over post-OP 3 days | 4.8% (3/63) (8.1% for total excision and 0% for enucleation) | 18 | No |
| 3[ | 35 | NA | NA | 24 | F (97%) M (3%) | Lobe (100%) | All with OP or IL | Total excision | 100 kV X-ray photon | 10/1 × 10; within post-OP 24 h | 11.8% (4/34)a | 60 | Transient erythema and post-radiation hyperpigmentation |
| 4[ | 145 | 174 | Japanese | NA | NA | Lobe (100%) | 13% (19/145) | Wedge excision + PS Simple excision + PS Simple excision + V–Y flap | 4-MeV electron | High dose: 15/3 × 5; over post-OP 3 days (20%) Low dose: 10/2 × 5; over post-OP 2 days (80%) | 4.0% (7/174) (4.7% for primary keloid and 0% for recurred keloid) | 18 | NA |
| 5[ | 21 | NA | African | 22 | F (77.5%) M (22.5%) | Lobe (72%) Helix (28%) | 33.3% (7/21) | Total excision ± rhomboid flap | 100 kV X-ray photon | 12/3 × 4; each Fr. on post-OP 3rd, 4th, and 5th day | 19.1% (4/21)a (14.3% for primary keloid and 28.6% for recurred keloid) | 18 | Depigmentation and atrophy after IL (100%), infection (1), and flap necrosis (1) |
| Our | 35 | 45 | Chinese (97.1%) Caucasian (2.9%) | 27.1 | F (85.7%) M (14.3%) | Lobe (71.1%) Helix (28.9%) | 17.8% (8/45) | Enucleation + core fillet flap | 6-MeV electron | 15/3 × 5 or 18/3 × 6; 1 Fr. in post-OP 24 h and 2 Fr. in post-OP 2–4 days | 6.7% (3/45) | 24.1 | 2.2% (1/45); seroma (1) |
aNumber of patients.
F female, Fr. Fraction, h hour, IL intralesional corticosteroid injection, M male, N number, NA not available, OP operation, PS primary suture, RT radiation therapy.